BioCorRx Inc. Reports First Quarter 2015 Financial Results

Los Angeles, May 20, 2015 (GLOBE NEWSWIRE) -- BioCorRx Inc. Reports First Quarter 2015 Financial Results

BioCorRx, Inc. (BICX), developer of the Start Fresh Program® used for the treatment of alcohol and opioid dependence, announces its first quarter 2015 Financial Results.

Revenues in the first quarter were $275,465, up over 110% from the first quarter of  2014.

Highlights for the quarter ending March 31, 2015:

·       Total revenue was $275,465, compared to total revenue of $130,829 for the first quarter of 2014.

·       Total operating expenses were $283,134, compared to operating expenses of $522,555 for first quarter 2014 which reflect a decrease of 46%.

"We continue to see a great drive in our business model with increased revenues. Last year ended with what we believe was a fantastic year for the Company highlighted by many key accomplishments including elimination of convertible debt, expanding our core market and being cash flow positive. We believe we are now poised for a solid 2015, building upon strong continued interest and support from physicians and clinics offering the Start Fresh Program. Our branding efforts continue to give the Company much broader visibility in the addiction community," said Lourdes Felix, CFO of BioCorRx Inc.

For additional information please see the Company's Quarterly Report on Form 10-Q for the period ended March 31, 2015 on

Visit BioCorRx, Inc.'s investor relations website at to receive the most up to date company information.

Click here to view Recent National Television Media on the BioCorRx YouTube Channel

Click here for company Facebook page for more stories and media coverage

About BioCorRx, Inc.

BioCorRx, Inc. ® (OTCQB: BICX) is an addiction treatment and rehabilitation company offering a unique approach to the treatment of substance abuse addiction. The Start Fresh Program®, a medication-assisted treatment program, consists of two components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers therapeutic levels of the drug Naltrexone, an opioid antagonist that significantly reduces physical cravings for alcohol and opioids, into the body. The second component of the program developed by BioCorRx, Inc. is a one on one coaching program specifically tailored for the treatment of alcoholism and other substance abuse addictions. Clinic reports show that the treatment program can be successful for individuals who complete the program. For more information on BICX, visit

Safe Harbor Statement

The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.

CONTACT: Investor Relations
, Inc.


BioCorRx logo

Source: BioCorRx